Skip to main content

GNS Healthcare Nets SAIC Contract to Analyze NCI's Drug Interaction Data

Premium

GNS Healthcare said this week that it has signed a subcontract with SAIC-Frederick to create in silico simulations of drug interaction data generated by applying several well-known cancer treatments to the National Cancer Institute's NCI-60 cancer cell line panel.

Financial terms of the agreement were not disclosed.

GNS said that in the first phase of the project, it will use its Reverse Engineering and Forward Simulation platform to build computer models from transcriptional profiling data previously collected by NCI from the application of several drugs to the panel.

The list of drugs includes doxorubicin X2, Millennium Pharmaceuticals' Velcade (bortezimib), paclitaxel, Bristol-Myers Squibb's Sprycel (dasatinib), Pfizer's Sutent (sunitinib), and Wyeth's Rapamycin.

The simulations are expected to provide insights into key genetic and molecular mechanisms of drug efficacy and resistance in cancer by connecting drug doses to transcriptional networks to endpoints, GNS said.

GNS also plans to build versions of the computer models that may be made available more broadly to cancer scientists for their own research via a web interface.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.